In the STEP trials, some participants taking semaglutide lost substantial weight without reporting gastrointestinal side effects. That presents a useful puzzle: if nausea explains the weight loss, how did those participants lose weight without it? The comparison challenges the idea that feeling sick is evidence a medicine is working, although it cannot reveal every individual's biology.[1] A separate trial measuring appetite and food intake helps explain how weight loss and tolerability can coexist.[2]
Symptoms and weight loss are different outcomes
Gastrointestinal, or GI, refers to the digestive tract. Researchers pooled safety data from three 68-week STEP trials involving 2,117 adults assigned to injected semaglutide and 1,262 assigned to placebo. Nausea occurred in 43.9% versus 16.1%, respectively; diarrhoea, vomiting and constipation were also common. Most reported GI events were mild or moderate, but 4.3% of semaglutide participants permanently discontinued treatment because of GI events.[1]
Those figures establish a tolerability burden. They do not establish that symptoms cause the treatment benefit. An adverse event records something unwanted during treatment; body-weight change measures a different outcome. Showing that a medicine affects both does not explain the connection between them.
The trial populations also differed. STEP 2 included adults with type 2 diabetes, while STEP 1 and STEP 3 excluded diabetes; their accompanying behavioural interventions differed too. Their weight-loss results therefore need to remain attached to their study contexts.[1]
What the nausea analysis actually estimated
Among semaglutide participants still receiving treatment and measured at week 68, average weight loss ranged from 9.6% to 17.1% across the three trials in those without GI events. Among those with GI events, averages ranged from 11.4% to 17.7%. Substantial loss occurred in both groups.[1]
Researchers then used mediation analysis: a statistical method that estimates how much of a treatment effect passes through an intermediate event. Here, the proposed chain was treatment, then GI symptoms, then weight loss. Less than one percentage point of the additional weight loss associated with semaglutide versus placebo was estimated to be mediated by GI events. The result was similar when the analysis focused on nausea, diarrhoea and vomiting.[1]
That is evidence against symptoms being the main explanation, with important limits. These were exploratory, post-hoc analyses. People were randomized to treatment, not to nausea. The model assumed no relevant unmeasured confounding between symptoms and weight outcomes, and symptom timing was not fully accounted for. The descriptive comparison excluded people who stopped treatment before week 68.[1] Consequently, the findings cannot prove that nausea contributes nothing biologically, or turn the presence or absence of nausea into an effectiveness test for one person.
Appetite can change without feeling ill
A smaller randomized, blinded trial studied injected semaglutide against placebo in 72 adults with obesity over 20 weeks. Participants reported hunger and fullness after a standardized breakfast, then ate lunch with the amount left to their appetite. Researchers measured the food consumed rather than relying only on recollection.[2]
At week 20, semaglutide participants reported less hunger, more fullness and greater satiety—the feeling of remaining satisfied after eating. Their measured lunch energy intake was 35% lower than the placebo group's. Average nausea ratings during the assessment were low in both groups.[2] These findings are compatible with appetite regulation contributing to reduced intake without prominent nausea at that visit; they do not show that nobody experienced nausea earlier.
| What was measured | Finding | What it cannot establish |
|---|---|---|
| Appetite ratings | Less hunger and greater fullness with semaglutide.[2] | How much someone eats throughout everyday life. |
| Measured lunch | Energy intake was 35% lower versus placebo.[2] | A 35% reduction across every meal or day. |
| Body weight | Mean reductions were 9.9% versus 0.4% at week 20.[2] | A guaranteed individual result or a lifelong trajectory. |
The weight figures were descriptive outcomes. This was a small, single-centre study in adults with obesity without diabetes, using a particular injected formulation and protocol. It was not a comparison of all GLP-1 medicines, oral formulations or populations.[2]
The stomach-emptying result needs its timepoint
Gastric emptying means the movement of stomach contents into the intestine. The appetite trial assessed it indirectly through paracetamol absorption after a meal, rather than directly imaging the meal's passage. At week 20, the researchers found no evidence of delayed emptying using that method.[2]
The main absorption measure was actually 8% higher with semaglutide; that difference was no longer statistically significant after adjustment for week-20 body weight. Other absorption measures did not indicate a delay.[2] This is a finding about specific measurements at a specific visit.
Paracetamol absorption has limitations as a marker of solid-food emptying, and effects can differ with treatment duration. The study therefore does not establish that semaglutide never affects gastric emptying, that earlier effects were absent, or that stomach symptoms have only one cause.[2] Appetite, nausea and gastric emptying should remain separate questions when interpreting the evidence.
Feeling well is not failure; feeling unwell still matters
Neither nausea nor its absence can substitute for clinical assessment of treatment response. Persistent or severe symptoms deserve medical evaluation. The Wegovy prescribing information warns about severe GI reactions, dehydration-associated kidney injury and acute pancreatitis; persistent or severe abdominal pain can be a pancreatitis symptom. It also states that Wegovy is not recommended in severe gastroparesis, a condition involving markedly delayed stomach emptying.[3]
These risks matter even when the medicine and its manufacture are regulated. The FDA separately warns that unapproved GLP-1 products have not undergone its review for safety, effectiveness and quality, and describes reports of dosing errors, some requiring hospitalization. It also warns about products falsely marketed as research-only while being sold for human use.[4]
Laboratory research materials should not be consumed or self-administered. A reagent can be well characterized for laboratory work without that characterization establishing a clinically suitable formulation, sterility for injection or safety in people. Purity alone cannot answer those questions, and reconstitution cannot supply missing clinical evidence. Trial findings about a specified medicine do not validate a research material carrying the same compound name.[2][4]
Source note: This article uses the full Wharton and Friedrichsen papers, relevant current Wegovy warning sections and FDA safety information retrieved October 23, 2026. The mediation analysis is exploratory; the gastric-emptying assessment is indirect and timepoint-specific. This is editorial source review, not medical review or a Chudik experiment.